Emergence of Peptides
The emergence of peptides in the pharmaceutical business
Feb 08 2017
“Peptide attributes originally considered troublesome with respect to drug development may now turn out to be more convenient rather than unfavourable.
Besides characteristic high target affinity, biological peptides often exhibit higher than expected stability. Clearly natural selective pressure has optimised these biomolecules beyond what can be anticipated solely on the basis of their chemical nature. This concept is gradually finding its way into the pharma and biotech industry, as illustrated by a rise in medicinal peptide patent applications and developmental work.”
There is no clinical tryout at the moment of MuTaTo in Israel or outside of Israel.Contact us at email@example.com
Our team are research scientists (Ph.D.) and are not attending Dr.
We are working now for the 20th year entering our 21th year of R&D effort (in June 2022).
We don’t have a Clinique and we can not advise nor refer to any specific case.
We initially intend to target: lung, colon, head & neck cancers.
The treatment, in any case, has to be individually adapted to the patient.
We are a small team and have an influx of e-mail.
We try to answer at least initial emails but can not promise it.
This website may contain certain statements, estimations, projections, assessments and other information with respect to the anticipated future performance of the Company and/or its market and involve risks and uncertainties. Actual results or future business decisions of the Company may differ materially from any expectations, projections or predictions made or implicated in statements made in this website. While the Company believes that the information contained herein is accurate, it expressly disclaims any and all liability for representations or warranties, expressed or implied, contained in, or for omissions from, this website or any other communication transmitted or made available herein. Any prospective website user acknowledges his/her responsibility to perform a due diligence review prior to consummating a transaction with the Company. Included in this website are certain declarations by the Company with respect to its anticipated future performance. These declarations are based on estimates and assumptions by the Company that are subject to economic and competitive uncertainties beyond the control of the Company. The Company does not provide representation or warranty with regard to the declarations and there can be no assurance that the future results will be realized or that actual results will not be significantly different from those projected. The Company is not obligated to update or revise any future declarations. The Company and its respective affiliates, directors, officers, employees, consultants and representatives expressly disclaim any and all liability relating to or resulting from the utilization of any information contented in this website. The Company does not have any obligation to provide with access to additional information.